Metastasis From Malignant Tumor Of Thyroid — Patent Landscape
1
Approved drugs
56
Active US patents
60/100
Avg vulnerability
$700M
Annual revenue covered
Originators in Metastasis From Malignant Tumor Of Thyroid
Cliff calendar — next 15 years
18
37
28
38
10
39
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Retevmo
SELPERCATINIB
|
Eli Lilly | 56 | 60 | $700M | 2037-10-10 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 10172851 | Retevmo | method of use | 75 | 2037-10-10 |
| 10172851 | Retevmo | method of use | 75 | 2037-10-10 |
| 10172851 | Retevmo | method of use | 75 | 2037-10-10 |
| 10172851 | Retevmo | method of use | 75 | 2037-10-10 |
| 10137124 | Retevmo | method of use | 75 | 2037-10-10 |
| 10137124 | Retevmo | method of use | 75 | 2037-10-10 |
| 10137124 | Retevmo | method of use | 75 | 2037-10-10 |
| 10137124 | Retevmo | method of use | 75 | 2037-10-10 |
| 12138250 | Retevmo | method of use | 75 | 2038-10-10 |
| 12138250 | Retevmo | method of use | 75 | 2038-10-10 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 10112942 | Retevmo | composition of matter | 4 | 2037-10-10 |
| 10112942 | Retevmo | composition of matter | 4 | 2037-10-10 |
| 10112942 | Retevmo | composition of matter | 17 | 2037-10-10 |
| 10112942 | Retevmo | composition of matter | 17 | 2037-10-10 |
| 10112942 | Retevmo | composition of matter | 17 | 2037-10-10 |
| 10112942 | Retevmo | composition of matter | 17 | 2037-10-10 |
| 12138250 | Retevmo | other | 62 | 2039-04-10 |
| 12138250 | Retevmo | other | 62 | 2039-04-10 |
| 12138250 | Retevmo | other | 62 | 2039-04-10 |
| 10786489 | Retevmo | other | 62 | 2039-04-10 |
Related
- Metastasis From Malignant Tumor Of Thyroid — full disease profile
- AI Patent Landscape Report — type "metastasis from malignant tumor of thyroid" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner